Cargando…

Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients

BACKGROUND: The one-stage assay is the most common method to measure factor VIII activity (FVIII : C) in hemophilia A patients. The chromogenic assay is another two-stage test involving purified coagulation factors followed by factor Xa-specific chromogenic substrate. AIM: This study aimed to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Owaidah, Tarek M., Alzahrani, Hazzaa A., Al-Numair, Nouf S., Alnosair, Abdulmjeed O., Aguilos, Amelita M., Saleh, Mahasen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499282/
https://www.ncbi.nlm.nih.gov/pubmed/32963537
http://dx.doi.org/10.1155/2020/8768074
_version_ 1783583681730838528
author Owaidah, Tarek M.
Alzahrani, Hazzaa A.
Al-Numair, Nouf S.
Alnosair, Abdulmjeed O.
Aguilos, Amelita M.
Saleh, Mahasen
author_facet Owaidah, Tarek M.
Alzahrani, Hazzaa A.
Al-Numair, Nouf S.
Alnosair, Abdulmjeed O.
Aguilos, Amelita M.
Saleh, Mahasen
author_sort Owaidah, Tarek M.
collection PubMed
description BACKGROUND: The one-stage assay is the most common method to measure factor VIII activity (FVIII : C) in hemophilia A patients. The chromogenic assay is another two-stage test involving purified coagulation factors followed by factor Xa-specific chromogenic substrate. AIM: This study aimed to assess the discrepancy and correlation between the chromogenic and one-stage assays in measuring FVIII : C levels in hemophilia patients receiving Extended Half-Life Elocta® as a recombinant extended half-life coagulation factor. METHODS: We performed a study comparing the measurements of FVIII : C levels by the chromogenic versus the one-stage assays at different drug levels. Data of FVIII : C levels, dosage, and the time interval from administration to measurement were retrieved from the hospital records. The correlation, mean differences, and discrepancy between the two assays were calculated. The linear regression analysis was used to predict the time interval till reaching 1% FVIII : C. RESULTS: Fourteen patients with 56 samples were included in the study. Of them, 13 patients were receiving Elocta® as a prophylactic, while one was receiving Elocta® on demand. One-third of these samples showed a discrepancy between the chromogenic and one-stage assays. The two assays were well correlated. Mean differences were significant at the individual and the time interval level. The time since the last Elocta® injection could significantly predict FVIII : C levels (β = 0.366, P < 0.001). CONCLUSION: Our findings suggested a significant difference between both methods; the FVIII : C levels measured by the one-stage assay were less than those estimated by the chromogenic assay. However, the measurements of FVIII levels by the two assays were well correlated but discrepant in one-third of the samples. The levels of FVIII : C reach 1% after 5.4 days since the last Elocta® administration.
format Online
Article
Text
id pubmed-7499282
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-74992822020-09-21 Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients Owaidah, Tarek M. Alzahrani, Hazzaa A. Al-Numair, Nouf S. Alnosair, Abdulmjeed O. Aguilos, Amelita M. Saleh, Mahasen Adv Hematol Clinical Study BACKGROUND: The one-stage assay is the most common method to measure factor VIII activity (FVIII : C) in hemophilia A patients. The chromogenic assay is another two-stage test involving purified coagulation factors followed by factor Xa-specific chromogenic substrate. AIM: This study aimed to assess the discrepancy and correlation between the chromogenic and one-stage assays in measuring FVIII : C levels in hemophilia patients receiving Extended Half-Life Elocta® as a recombinant extended half-life coagulation factor. METHODS: We performed a study comparing the measurements of FVIII : C levels by the chromogenic versus the one-stage assays at different drug levels. Data of FVIII : C levels, dosage, and the time interval from administration to measurement were retrieved from the hospital records. The correlation, mean differences, and discrepancy between the two assays were calculated. The linear regression analysis was used to predict the time interval till reaching 1% FVIII : C. RESULTS: Fourteen patients with 56 samples were included in the study. Of them, 13 patients were receiving Elocta® as a prophylactic, while one was receiving Elocta® on demand. One-third of these samples showed a discrepancy between the chromogenic and one-stage assays. The two assays were well correlated. Mean differences were significant at the individual and the time interval level. The time since the last Elocta® injection could significantly predict FVIII : C levels (β = 0.366, P < 0.001). CONCLUSION: Our findings suggested a significant difference between both methods; the FVIII : C levels measured by the one-stage assay were less than those estimated by the chromogenic assay. However, the measurements of FVIII levels by the two assays were well correlated but discrepant in one-third of the samples. The levels of FVIII : C reach 1% after 5.4 days since the last Elocta® administration. Hindawi 2020-09-09 /pmc/articles/PMC7499282/ /pubmed/32963537 http://dx.doi.org/10.1155/2020/8768074 Text en Copyright © 2020 Tarek M. Owaidah et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Owaidah, Tarek M.
Alzahrani, Hazzaa A.
Al-Numair, Nouf S.
Alnosair, Abdulmjeed O.
Aguilos, Amelita M.
Saleh, Mahasen
Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients
title Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients
title_full Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients
title_fullStr Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients
title_full_unstemmed Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients
title_short Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients
title_sort assessing the performance of extended half-life coagulation factor viii, fc fusion protein by using chromogenic and one-stage assays in saudi hemophilia a patients
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499282/
https://www.ncbi.nlm.nih.gov/pubmed/32963537
http://dx.doi.org/10.1155/2020/8768074
work_keys_str_mv AT owaidahtarekm assessingtheperformanceofextendedhalflifecoagulationfactorviiifcfusionproteinbyusingchromogenicandonestageassaysinsaudihemophiliaapatients
AT alzahranihazzaaa assessingtheperformanceofextendedhalflifecoagulationfactorviiifcfusionproteinbyusingchromogenicandonestageassaysinsaudihemophiliaapatients
AT alnumairnoufs assessingtheperformanceofextendedhalflifecoagulationfactorviiifcfusionproteinbyusingchromogenicandonestageassaysinsaudihemophiliaapatients
AT alnosairabdulmjeedo assessingtheperformanceofextendedhalflifecoagulationfactorviiifcfusionproteinbyusingchromogenicandonestageassaysinsaudihemophiliaapatients
AT aguilosamelitam assessingtheperformanceofextendedhalflifecoagulationfactorviiifcfusionproteinbyusingchromogenicandonestageassaysinsaudihemophiliaapatients
AT salehmahasen assessingtheperformanceofextendedhalflifecoagulationfactorviiifcfusionproteinbyusingchromogenicandonestageassaysinsaudihemophiliaapatients